Media coverage about Sage Therapeutics (NASDAQ:SAGE) has been trending somewhat positive on Saturday, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Sage Therapeutics earned a news impact score of 0.23 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 46.951840898805 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Here are some of the media headlines that may have impacted Accern’s rankings:

SAGE has been the topic of several analyst reports. J P Morgan Chase & Co cut their target price on shares of Sage Therapeutics from $99.00 to $85.00 and set an “overweight” rating on the stock in a report on Tuesday, September 12th. Stifel Nicolaus reiterated a “buy” rating and issued a $90.00 target price on shares of Sage Therapeutics in a report on Friday, July 14th. Canaccord Genuity cut their target price on shares of Sage Therapeutics from $110.00 to $81.00 and set a “buy” rating on the stock in a report on Tuesday, September 12th. Needham & Company LLC cut their target price on shares of Sage Therapeutics from $95.00 to $86.00 and set a “buy” rating on the stock in a report on Wednesday, September 13th. Finally, SunTrust Banks, Inc. reiterated a “buy” rating and issued a $82.00 target price (down from $95.00) on shares of Sage Therapeutics in a report on Wednesday, September 13th. Four analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $86.71.

Sage Therapeutics (SAGE) traded up $7.25 during trading on Friday, reaching $69.08. 919,080 shares of the company were exchanged, compared to its average volume of 435,173. Sage Therapeutics has a 1-year low of $38.47 and a 1-year high of $90.80.

Sage Therapeutics (NASDAQ:SAGE) last announced its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.98) by $0.01. The firm’s revenue was up .0% on a year-over-year basis. equities analysts forecast that Sage Therapeutics will post -7.36 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This article was first posted by Watch List News and is the property of of Watch List News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.watchlistnews.com/sage-therapeutics-sage-earning-somewhat-favorable-media-coverage-accern-reports/1678411.html.

Sage Therapeutics Company Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Insider Buying and Selling by Quarter for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.